The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys

Toxicologic Pathology

Volumn 32, Issue 3, 2004, Pages 295-308

  Losco, Patricia E ^a   Evans, Ellen W ^a   Barat, Stephen A ^a   Blackshear, Pamela E ^a   Reyderman, Larisa ^a   Fine, Jay S ^a   Bober, Loretta A ^a   Anthes, John C ^a   Mirro, Elmer J ^a   Cuss, Francis M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

arteriopathy; asthma therapy; chronic obstructive pulmonary disease; immunosuppression; metabolic effects; nonhuman primates; PDE4 inhibitor; T cells

Indexed keywords

N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PHOSPHODIESTERASE IV INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; ASTHMA; BACTERIAL INFECTION; BODY FAT; BODY WEIGHT; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; FOOD INTAKE; HEART; KIDNEY; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MONKEY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND; SEPSIS; STOMACH; STOMACH HEMORRHAGE; STOMACH MUCOSA; T LYMPHOCYTE; TACHYPHYLAXIS; THYMUS; TOXICITY TESTING; TOXICOKINETICS; VOMITING;

ANIMALS; ARTERIES; COLON; CYCLIC N-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOCYTES; MACACA FASCICULARIS; MALE; PHOSPHODIESTERASE INHIBITORS; QUINOLINES; SEPSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); EMESIS; MACACA FASCICULARIS; PRIMATES;

EID: 2542487257     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230490431493     Document Type: Article

References (69)

1. Albassam, M.A., Lillie, L.E., and Smith, G.S. (1993). Asymptomatic polyarteritis in a Cynomolgus monkey. Lab Anim Sci 43, 628-9.
2. Albassam, M.A., Smith, G.S., and Macallum, G.E. (1998). Arteriopathy induced by an adenosine agonist-antihypertensive in monkeys. Tox Pathol 26, 375-80.
3. Aoki, M., Fukunaga, M., Sugimoto, T., Hirano, Y., Kobayashi, M., Honda, K., and Yamada, T. (2001). Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 298, 1142-9.
4. Barnette, M.S., Grous, M., Cieslinski, L.B., Burman, M., Christensen, S.B., and Torphy, T.J. (1995). Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273, 1396-402.
5. Billah, M., Cooper, N., Minnicozzi, M., Warneck, J., Wang, P., Hey, J.A., Kreutner, W., Rizzo, C.A., Smith, S.R., Young, S., Chapman, R.W., Dyke, H., Shih, N.Y., Piwinski, J.J., Cuss, F.M., Montana, J., Ganguly, A.K., and Egan, R.W. (2002). Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 302, 127-38.
6. Bishop, S.P. (1989). Animal models of vasculitis. Toxicol Pathol 17, 109-17.
7. Bober, L.A., Grace, M.J., Pugliese-Sivo, C., Rojas-Triana, A., Waters, T., Sullivan, L.M., and Narula, S.K. (1995). The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacol 29, 111-9.
8. Boichot, E., Wallace, J.L., Germain, N., Corbel, M., Lugnier, C., Lagente, V., and Bourguignon, J.J. (2000). Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine. J Pharmacol Exp Ther 292, 647-53.
9. Boor, P.J., Gotlieb, A.I., Joseph, E.C., Kerns, W.D., Roth, R.A., and Tomaszewski, K.E. (1995). Contemporary issues in toxicology: Chemicalinduced vasculature injury. Toxicol and Appl Pharmacol 132, 177-95.
10. Burnouf, C., Pruniaux, M.P., and Szilagyi, C.M. (1998). Chapter 10: Phosphodiesterase 4 inhibitors. Ann Rep Med Chem 33, 91-109.
11. Campillo, N., and Paez, J. (2001). Novel bronchodilators in the treatment of asthma and COPD. Expert Opin Ther Patents 12, 53-63.
12. Clemo, F.A., Evering, W.E., Snyder, P.W., and Albassam, M.A. (2003). Differentiating spontaneous from drug-induced vascular injury in the dog Tox Pathol 31(Suppl.), 25-31.
13. Cortijo, J., Bou, J., Beleta, J., Cardelus, I., Llenas, J., Morcillo, E., and Gristwood, R.W. (1993). Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 108, 562-8.
14. de Boer, J., Philpott, A.J., van Amsterdam, R.G., Shahid, M., Zaagsma, J., and Nicholson, C.D. (1992). Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 106, 1028-34.
15. Dogterom, P., and Zbinden, G. (1992). Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: An overview. Crit Rev Toxicol 22, 203-41.
16. Essayan, D.M. (2001). Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108, 671-80.
17. Essayan, D.M., Huang, S.K., Kagey-Sobotka, A., and Lichtenstein, L.M. (1995). Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. Am J Respir Cell Mol Biol 13, 692-702.
18. Essayan, D.M., Huang, S.K., Kagey-Sobotka, A., and Lichtenstein, L.M. (1997). Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene-expression. J Allergy Clin Immunol 99, 28-37.
19. Essayan, D.M., Huang, S.K., Undem, B.J., Kagey-Sobotka, A., and Lichtenstein, L.M. (1994). Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 153, 3408-13.
20. Feigl, D., Feigl, A., and Edwards, J.E. (1986). Mycotic aneurysms of the aortic root: A pathologic study of 20 cases. Chest 90, 553-7.
21. Gantner, F., Gotz, C., Gekeler, V., Schudt, C., Wendel, A., and Hatzelmann, A. (1998). Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123, 1031-8.
22. Gibaldi, M., and Perrier, D. (1982). In Pharmacokinetics, 2nd edition pp. 409-17. Marcel Dekker, Inc., New York.
23. Giembycz, M.A. (2000). Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here? Drugs 59, 193-212.
24. Giembycz, M.A., Corrigan, C.J., Seybold, J., Newton, R., and Barnes, P.J. (1996). Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118, 1945-58.
25. Hanton, G., Le Net, J.L., and Abbott, D. (2000a). Cardiovascular toxicity of UK-57,831, a PDE III inhibitor, in rats. Internat J Toxicol 19(6), Abstracts for the 21st Annual Meeting of the American College of Toxicology, November 12-15, 2000, San Diego, CA. p. 28.
26. Hanton, G., Le Net, J.L., and Abbott, D. (2000b). Cardiovascular toxicity of UK-61,260, a PDE III inhibitor, in dogs Internat J Toxicol 19(6), Abstracts for the 21st Annual Meeting of the American College of Toxicology, November 12-15, 2000, San Diego, CA. p. 28.
27. Hanton, G., Le Net, J.L., and Ruty, B. (1995). Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. Arch Toxicol 69, 698-704.
28. Harleman, J.H., Joseph, E.C., Eden, R.J., Walker, T.F., Major, I.R., and Lamb, M.S. (1986). Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch Toxicol 59, 51-5.
29. Heaslip, R.J., and Evans, D.Y. (1995). Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 286, 281-90.
30. Howell, R.E., Muehsam, W.T., and Kinnier, W.J. (1990). Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci 46, 563-8.
31. Huang, Z., Ducharme, Y., Macdonald, D., and Robichaud, A. (2001). The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5, 432-8.
32. Isaacs, K.R., Joseph, E.C., and Betton, G.R. (1989). Coronary vascular lesions in dogs treated with phosphodiesterase III inhibitors. Toxicol Pathol 17, 153-63.
33. Jones, T.R., McAuliffe, M., McFarlane, C.S., Piechuta, H., Macdonald, D., and Rodger, I.W. (1997). Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can J Physiol Pharmacol 76, 210-7.
34. Joseph, E.C., Jones, H.B., and Kerns, W.D. (1996a). Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor. Toxicol Pathol 24, 429-35.
35. Joseph, E.C., Rees, J.A., and Dayan, A.D. (1996b). Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: An investigation of morphological, ultrastructural, and hemodynamic changes. Toxicol Pathol 24, 436-50.
36. Kammer, G.M. (1988). The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9, 222-9.
37. Kerns, W.D., and Joseph, E.C. (1991). Drug-induced lesions of the coronary artery, dog. In Cardiovascular and Musculoskeletal Systems (T. C. Jones, U. Mohr, and R. D. Hunt, eds.), pp. 84-90. Springer-Verlag, New York.
38. Langle, U.W., Bruggemann, S., Prentice, D.E., Ettlin, R.A., Richardson, B., Naef, R., and Cordier, A. (1993-1994). Hypertrophic osteopathy in rats following chronic administration of SDZ MNS 949, an isoquinoline. Exp Toxic Pathol 45, 473-9.
39. Larson, J.L., Pino, M.V., Geiger, L.E., and Simeone, C.R. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78, 44-9.
40. Lugnier, C., and Komas, N. (1993). Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur Heart J 14(Supplement 1), 141-8.
41. Means, J.R., Franklin, R.B., and Sandusky, G.E. (1989). Toxicological evaluation of the cardiotonic isomazole in the dog. Fundam Appl Toxicol 13, 418-28.
42. Mesfin, G.M., Piper, R.C., DuCharme, D.W., Carlson, R.G., Humphrey, S.J., and Zins, G.R. (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Tox Pathol 17, 164-81.
43. Mitsumori, K. (1990). Blood and lymphatic vessels. In Pathology of the Fischer Rat (G. Boorman, S. Eustis, M. Elwell, C. Montgomery, and W. Mackenzie, eds.), pp. 473-83. Academic Press, San Diego.
44. Nicholson, C.D., Challiss, R.A., and Shahid, M. (1991). Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. Trends Pharmacol Sci 12, 19-27.
45. Nielson, C.P., Vestal, R.E., Sturm, R.J., and Heaslip, R. (1990). Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 86, 801-8.
46. Ottonello, L., Morone, M.P., Dapino, P., and Dallegri, F. (1995). Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin Exp Immunol 101, 502-6.
47. Palfreyman, M.N., and Souness, J.E. (1996). Phosphodiesterase type IV inhibitors. Prog Med Chem 33, 1-52.
48. Pino, M.V., Valerio, M.G., Miller, G.K., Larson, J.L., Rosolia, D.L., Jayyosi, Z., Crouch, C.N., Trojanowski, J.Q., and Geiger, L.E. (1999). Toxicologic and carcinogenic effects of the type IV phosphodiesterase inhibitor RP 73401 on the nasal olfactory tissue in rats. Toxicol Pathol 27, 383-94.
49. Rao, R.R., Nair, T.B., Marathe, M.R., and Gangoli, S.D. (1985). Pre-clinical toxicity studies on the new nitroimidazole 1-methylsulphonyl-3-(1-methyl-5-nitroimidazole-2-yl)-2-imidazolidinone. Arzneimittelforschung 35, 1692-6.
50. Reeves, M.L., Leigh, B.K., and England, P.J. (1987). The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J 241, 535-41.
51. Reynolds, D.J. (1995). Where do 5-HT3 receptor antagonists act as anti-emetics? In Serotonin and the Scientific Basis of Anti-emetic Therapy (D. J. Reynolds, P. L. Andrews, and C. J. Davies, eds.), pp. 111-26. Oxford Clinical Communications, Oxford.
52. Robichaud, A., Savoie, C., Stamatiou, P.B., Tattersall, F.D., and Chan, C.C. (2001). PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacol 40, 262-9.
53. Robichaud, A., Tattersall, F.D., Choudhury, I., and Rodger, I.W. (1999). Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacol 38, 289-97.
54. Robicsek, S.A., Blanchard, D.K., Djeu, J.Y., Krzanowski, J.J., Szentivanyi, A., and Polson, J.B. (1991). Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 42, 869-77.
55. Ruben, Z., Deslex, P., Nash, G., Redmond, N.I., Poncet, M., and Dodd, D.C. (1989). Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: A possible genetic predilection. Toxicol Pathol 17, 145-52.
56. Sandusky, G.E., Means, J.R., and Yeager, H.K. (1993). Coronary artery toxicity in beagle dogs given indolidan, a type III phosphodiesterase inhibitor. Fundam Appl Toxicol 21, 228-35.
57. Sandusky, G.E., Vodicnik, M.J., and Tamura, R.N. (1991). Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan. Fundam Appl Toxicol 16, 198-209.
58. Schudt, C., Winder, S., Forderkunz, S., Hatzelmann, A., and Ullrich, V. (1991). Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Ca. Naunyn-Schmiedeberg's Arch Pharmacol 344, 682-90.
59. Slim, R.M., Song, Y., Albassam, M., and Dethloff, L.A. (2003). Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol Pathol 31, 638-45.
60. Sneller, M.C. (2002). Vasculitis secondary to bacterial, fungal, and parasitic infection. In Inflammatory Diseases of Blood Vessels (G. S. Hoffman and C. M. Weyand, eds.), pp. 599-608. Marcel Dekker, Inc., New York.
61. Spina, D. (2000). The potential of PDE4 inhibitors in asthma or COPD. Current Opin Invest Drugs 1, 204-13.
62. Srivastava, R. (1989). Inhibition of neutrophil response by curcumin. Agents Actions 28, 298-303.
63. Torphy, T.J. (1998). Phosphodiesterase enzymes Molecular targets for novel antiasthma agents. Am J Resp Crit Care Med 157, 351-70.
64. Vogel, B., Kolopp, M., de Brugerolle de Fraissinette, A., Singer, T., Ettlin, R.A., Birnbaum, I., and Cordier, A. (1999). Minipigs in safety assessment of a phosphodiesterase type IV inhibitor for the treatment of inflammatory skin diseases. Toxicologist 48(1-S), 323.
65. Wachtel, H. (1982). Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3’,5’-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77, 309-16.
66. Westwood, F.R., Iswaran, T.J., and Greaves, P. (1990). Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153,110) to the rat. Fundam Appl Tox 14, 797-809.
67. Westwood, F.R., Iswaran, T.J., and Greaves, P. (1991). Long-term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, harderian gland, and intestinal mucosa Toxicol Pathol 19, 214-23.
68. Yoshino, N., Ami, Y., Terao, K., Tashiro, F., and Honda. M. (2000). Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using antihuman cross-reactive antibodies. Exp Anim 49, 97-110.
69. Zhang, J., Herman, E.H., Knapton, A., Chadwick, D.P., Whitehurst, V.E., Koerner, J.E., Papoian, T., Ferrans, V.J., and Sistare, F.D. (2002). SK&F 95654-induced acute cardiovascular toxicity in Sprague—Dawley rats— histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol 30, 28-40.